{
  "ticker": "TTX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02963015",
  "id": "02963015",
  "pages": 5,
  "price_sensitive": false,
  "date": "20250627",
  "time": "1458",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250627/pdf/06l5zqx2d1h6w3.pdf",
  "summary": "- **Document Type**: Supplementary Prospectus (clarifications to original Prospectus dated 4 June 2025).  \n- **Key Changes**:  \n  - **Revised Market Opportunity**: Total addressable market (TAM) for Tetramatrix\u2122 platform now stated as **US$6.8B (2025)**, growing to **US$9.5B by 2030**, but flagged as \"estimate only\" with risk disclosure.  \n  - **Going Concern Risk**: Auditor issued opinion with **material uncertainty** on going concern due to no revenue generation.  \n  - **Commercialization Timeline**: All products **not yet commercialized**; timelines outlined in Section 2.10 of original Prospectus.  \n  - **Partnership Updates**:  \n    - Provisional agreement with **Henry Schein** for dental/oral applications.  \n    - Negotiations with global companies for orthopedic products.  \n    - Joint ventures with **Tutelix** (urology) and **BioOptix** (ophthalmic spacing).  \n- **Capital Raise Context**: No new capital raise details; supplements original Prospectus (structure/pricing not provided here).  \n\n**No material trading or capital-raising actions required**. Changes primarily refine risk disclosures and commercial timelines.",
  "usage": {
    "prompt_tokens": 2748,
    "completion_tokens": 257,
    "total_tokens": 3005,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-27T05:42:05.627037"
}